Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 08, 2022

SELL
$23.14 - $49.68 $46 Million - $98.9 Million
-1,990,058 Reduced 72.97%
737,152 $25.5 Million
Q1 2022

May 05, 2022

SELL
$27.77 - $64.4 $67 Million - $155 Million
-2,411,636 Reduced 46.93%
2,727,210 $120 Million
Q4 2021

Jan 20, 2022

BUY
$54.9 - $105.21 $13.4 Million - $25.6 Million
243,565 Added 4.98%
5,138,846 $323 Million
Q3 2021

Oct 19, 2021

BUY
$105.0 - $178.37 $89.7 Million - $152 Million
853,991 Added 21.13%
4,895,281 $516 Million
Q2 2021

Aug 02, 2021

BUY
$125.11 - $180.0 $22 Million - $31.7 Million
176,166 Added 4.56%
4,041,290 $715 Million
Q1 2021

May 06, 2021

BUY
$126.27 - $191.71 $1.89 Million - $2.87 Million
14,975 Added 0.39%
3,865,124 $516 Million
Q4 2020

Feb 10, 2021

BUY
$81.94 - $135.34 $20.3 Million - $33.5 Million
247,713 Added 6.88%
3,850,149 $521 Million
Q3 2020

Nov 12, 2020

BUY
$73.3 - $89.48 $21.4 Million - $26.1 Million
291,954 Added 8.82%
3,602,436 $300 Million
Q2 2020

Aug 12, 2020

BUY
$48.82 - $82.53 $9.55 Million - $16.1 Million
195,682 Added 6.28%
3,310,482 $272 Million
Q1 2020

May 08, 2020

BUY
$39.1 - $62.9 $2.94 Million - $4.72 Million
75,100 Added 2.47%
3,114,800 $160 Million
Q4 2019

Feb 10, 2020

SELL
$29.79 - $43.06 $2.87 Million - $4.15 Million
-96,400 Reduced 3.07%
3,039,700 $126 Million
Q3 2019

Nov 07, 2019

BUY
$30.47 - $37.65 $32 Million - $39.5 Million
1,049,717 Added 50.31%
3,136,100 $101 Million
Q2 2019

Aug 08, 2019

BUY
$25.73 - $35.79 $52.6 Million - $73.1 Million
2,043,683 Added 4786.14%
2,086,383 $72.8 Million
Q1 2019

May 01, 2019

BUY
$21.71 - $31.54 $927,017 - $1.35 Million
42,700 New
42,700 $0

Others Institutions Holding ZLAB

About Zai Lab Ltd


  • Ticker ZLAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,908,704
  • Market Cap $2.59B
  • Description
  • Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...
More about ZLAB
Track This Portfolio

Track Baillie Gifford & CO Portfolio

Follow Baillie Gifford & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

News

Stay updated on Baillie Gifford & CO with notifications on news.